1
James Aggen, John H Griffin, Mathai Mammen, Daniel Marquess, Edmund J Moran, David Oare: Muscarinic receptor antagonists. Theravance, Jeffrey A Hagenah, Joyce G Cohen, February 17, 2004: US06693202 (123 worldwide citation)

Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modu ...


2

3
Paul R Fatheree, Martin S Linsell, Daniel D Long, Daniel Marquess, Edmund J Moran, Matthew B Nodwell, S Derek Turner, James Aggen: Cross-linked glycopeptide-cephalosporin antibiotics. Theravance, Jeffrey A Hagenah, December 13, 2005: US06974797 (22 worldwide citation)

This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using suc ...


4
Paul R Fatheree, Martin S Linsell, Daniel D Long, Daniel Marquess, Edmund J Moran, Matthew B Nodwell, S Derek Turner, James Aggen: Cross-linked glycopeptide—cephalosporin antibiotics. Theravance, Jeffrey A Hagenah, March 11, 2008: US07341993 (11 worldwide citation)

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using suc ...


5
Edmund J Moran, John R Jacobsen, James Aggen: Aryl aniline β2 adrenergic receptor agonists. Theravance, Roberta P Saxon, Jeffrey A Hagenah, September 27, 2005: US06949568 (11 worldwide citation)

The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for prep ...


6
Paul R Fatheree, Martin S Linsell, Daniel D Long, Daniel Marquess, Edmund J Moran, Matthew B Nodwell, S Derek Turner, James Aggen: Cross-linked glycopeptide-cephalosporin antibiotics. Theravance, Jeffrey A Haganah, November 3, 2009: US07612037 (9 worldwide citation)

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using suc ...


7
Edmund J Moran, John R Jacobsen, James Aggen: adrenergic receptor agonists, Aryl aniline β. Theravance, Jeffrey A Hagenah, Roberta P Saxon, October 24, 2006: US07125892 (7 worldwide citation)

The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1–R13 and w have any of the values described in the specification. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases assoc ...


8
Edmund J Moran, John R Jacobsen, Michael R Leadbetter, Matthew B Nodwell, Sean G Trapp, James Aggen, Timothy J Church: adrenergic receptor agonists, Aryl aniline β. Theravance, Jeffrey A Hagenah, Roberta P Saxon, September 1, 2009: US07582765 (1 worldwide citation)

The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compo ...


9
Paul R Fatheree, Martin S Linsell, Daniel D Long, Daniel Marquess, Edmund J Moran, Matthew B Nodwell, S Derek Turner, James Aggen: Cross-linked glycopeptide-cephalosporin antibiotics. Theravance, July 10, 2003: US20030130173-A1 (1 worldwide citation)

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using suc ...


10
James Aggen, John H Griffin, Mathai Mammen, Daniel Marquess, Edmund J Moran, David Oare: Muscarinic receptor antagonists. Theravance, Jeffrey A Hagenah, Shelley Eberle, November 25, 2008: US07456203

Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modu ...



Click the thumbnails below to visualize the patent trend.